OBJECTIVES: Prostate biopsy (Bx) has for 3 decades been performed in a systematic, but blind fashion using 2D ultrasound (US). Herein is described the initial clinical evaluation of a 3D Bx tracking and targeting device (Artemis; Eigen, Grass Valley, CA). Our main objective was to test accuracy of the new 3D method in men undergoing first and follow-up Bx to rule out prostate cancer (CaP). MATERIALS AND METHODS: Patients in the study were men ages 35-87 years (66.1 ± 9.9), scheduled for Bx to rule out CaP, who entered into an IRB-approved protocol. A total of 218 subjects underwent conventional trans-rectal US (TRUS); the tracking system was then attached to the US probe; the prostate was scanned and a 3D reconstruction was created. All Bx sites were visualized in 3D and tracked electronically. In 11 men, a pilot study was conducted to test ability of the device to return a Bx to an original site. In 47 men, multi-parametric 3 Tesla MRI, incorporating T2-weighted images, dynamic contrast enhancement, and diffusion-weighted imaging, was performed in advance of the TRUS, allowing the stored MRI images to be fused with real-time US during biopsy. Lesions on MRI were delineated by a radiologist, assigned a grade of CaP suspicion, and fused into TRUS for biopsy targeting. RESULTS: 3D Bx tracking was completed successfully in 180/218 patients, with a success rate approaching 95% among the last 50 men. Average time for Bx with the Artemis device was 15 minutes with an additional 5 minutes for MRI fusion and Bx targeting. In the tracking study, an ability to return to prior Bx sites (n=32) within 1.2 ± 1.1 mm SD was demonstrated and was independent of prostate volume or location of Bx site. In the MRI fusion study, when suspicious lesions were targeted, a 33% Bx-positivity rate was found compared with a 7% positivity rate for systematic, nontargeted Bx (19/57 cores vs. 9/124 cores, P=0.03). CONCLUSION: Use of 3D tracking and image fusion has the potential to transform MRI into a clinical tool to aid biopsy and improve current methods for diagnosis and follow-up of CaP.
OBJECTIVES: Prostate biopsy (Bx) has for 3 decades been performed in a systematic, but blind fashion using 2D ultrasound (US). Herein is described the initial clinical evaluation of a 3D Bx tracking and targeting device (Artemis; Eigen, Grass Valley, CA). Our main objective was to test accuracy of the new 3D method in men undergoing first and follow-up Bx to rule out prostate cancer (CaP). MATERIALS AND METHODS:Patients in the study were men ages 35-87 years (66.1 ± 9.9), scheduled for Bx to rule out CaP, who entered into an IRB-approved protocol. A total of 218 subjects underwent conventional trans-rectal US (TRUS); the tracking system was then attached to the US probe; the prostate was scanned and a 3D reconstruction was created. All Bx sites were visualized in 3D and tracked electronically. In 11 men, a pilot study was conducted to test ability of the device to return a Bx to an original site. In 47 men, multi-parametric 3 Tesla MRI, incorporating T2-weighted images, dynamic contrast enhancement, and diffusion-weighted imaging, was performed in advance of the TRUS, allowing the stored MRI images to be fused with real-time US during biopsy. Lesions on MRI were delineated by a radiologist, assigned a grade of CaP suspicion, and fused into TRUS for biopsy targeting. RESULTS: 3D Bx tracking was completed successfully in 180/218 patients, with a success rate approaching 95% among the last 50 men. Average time for Bx with the Artemis device was 15 minutes with an additional 5 minutes for MRI fusion and Bx targeting. In the tracking study, an ability to return to prior Bx sites (n=32) within 1.2 ± 1.1 mm SD was demonstrated and was independent of prostate volume or location of Bx site. In the MRI fusion study, when suspicious lesions were targeted, a 33% Bx-positivity rate was found compared with a 7% positivity rate for systematic, nontargeted Bx (19/57 cores vs. 9/124 cores, P=0.03). CONCLUSION: Use of 3D tracking and image fusion has the potential to transform MRI into a clinical tool to aid biopsy and improve current methods for diagnosis and follow-up of CaP.
Authors: A R Padhani; C J Gapinski; D A Macvicar; G J Parker; J Suckling; P B Revell; M O Leach; D P Dearnaley; J E Husband Journal: Clin Radiol Date: 2000-02 Impact factor: 2.350
Authors: Piotr Kozlowski; Silvia D Chang; Edward C Jones; Kenneth W Berean; Henry Chen; S Larry Goldenberg Journal: J Magn Reson Imaging Date: 2006-07 Impact factor: 4.813
Authors: G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz Journal: Radiology Date: 1997-06 Impact factor: 11.105
Authors: Jurgen J Fütterer; Stijn W T P J Heijmink; Tom W J Scheenen; Jeroen Veltman; Henkjan J Huisman; Pieter Vos; Christina A Hulsbergen-Van de Kaa; J Alfred Witjes; Paul F M Krabbe; Arend Heerschap; Jelle O Barentsz Journal: Radiology Date: 2006-09-11 Impact factor: 11.105
Authors: Jurgen J Fütterer; Marc R Engelbrecht; Henkjan J Huisman; Gerrit J Jager; Christina A Hulsbergen-van De Kaa; J Alfred Witjes; Jelle O Barentsz Journal: Radiology Date: 2005-11 Impact factor: 11.105
Authors: Andriy Fedorov; Kemal Tuncali; Fiona M Fennessy; Junichi Tokuda; Nobuhiko Hata; William M Wells; Ron Kikinis; Clare M Tempany Journal: J Magn Reson Imaging Date: 2012-05-29 Impact factor: 4.813
Authors: Nima Nassiri; Daniel J Margolis; Shyam Natarajan; Devi S Sharma; Jiaoti Huang; Frederick J Dorey; Leonard S Marks Journal: J Urol Date: 2016-09-14 Impact factor: 7.450
Authors: Chen-Wei Wei; Thu-Mai Nguyen; Jinjun Xia; Bastien Arnal; Emily Y Wong; Ivan M Pelivanov; Matthew O'Donnell Journal: IEEE Trans Ultrason Ferroelectr Freq Control Date: 2015-02 Impact factor: 2.725
Authors: Edward Chang; Tonye A Jones; Shyam Natarajan; Devi Sharma; Demetrios Simopoulos; Daniel J Margolis; Jiaoti Huang; Frederick J Dorey; Leonard S Marks Journal: J Urol Date: 2017-07-18 Impact factor: 7.450
Authors: John A Onofrey; Lawrence H Staib; Saradwata Sarkar; Rajesh Venkataraman; Cayce B Nawaf; Preston C Sprenkle; Xenophon Papademetris Journal: Med Image Anal Date: 2017-04-12 Impact factor: 8.545
Authors: Geoffrey A Sonn; Edward Chang; Shyam Natarajan; Daniel J Margolis; Malu Macairan; Patricia Lieu; Jiaoti Huang; Frederick J Dorey; Robert E Reiter; Leonard S Marks Journal: Eur Urol Date: 2013-03-17 Impact factor: 20.096